Basra, Mohamed K. A., Pereira, F., Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646, Piguet, Vincent and Salek, Mir-saeed 2012. EuroQol-5D (EQ-5D): its Use in Pharmacoeconomic Studies in Dermatology [Abstract]. Journal of Investigative Dermatology 132 (S2) , S72. 10.1038/jid.2012.300 |
Abstract
Despite its lack of specific dermatology origin, the EQ-5D questionnaire is being used as a utility measure in clinical and pharmaco-economic studies in dermatology. The aim of this review is to examine the use of EQ-5D in pharmaco-economic studies in dermatology. A literature search involving six online search engines and hand search of journals in the medical school library was carried out using search terms: EQ-5D, skin disease, dermatology, economic analysis, cost-effectiveness, cost minimisation, cost-utility, cost of illness, cost-benefit, pharmaco-economics. Nineteen articles and one abstract published between 2003 and 2011 were identified that had EQ-5D as an outcome measure in cost-of-illness, cost-effectiveness and cost-utility analysis studies. Seven were cost-of-illness studies on atopic eczema, herpes zoster, psoriasis, and acne demonstrating different levels of burden measured as cost of illness. There was only one cost-effectiveness study. The results indicated that home ultraviolet-B phototherapy for psoriasis was not more expensive than phototherapy in an outpatient department. Thirteen cost-utility studies evaluated the cost versus utility of various interventions for five different skin diseases: chronic hand eczema (alitretinoin), malignant melanoma (interferon-alpha), atopic eczema (tacrolimus), herpes zoster (vaccines) and psoriasis (home vs out-patient phototherapy, biologics, MTX, ciclosporin, topical therapy, in-office vs online care). Although the EQ-5D allows the possibility of measuring utility and comparisons with non-dermatological diseases, it may not detect important and specific issues pertinent to dermatological diseases. In order to understand the true economic burden of skin disease, the EQ-5D should be used in conjunction with a skin disease-specific quality of life measure in clinical trials to give a comprehensive evaluation of the impact of intervention on socio-economic burden.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Pharmacy Systems Immunity Research Institute (SIURI) |
Subjects: | R Medicine > RM Therapeutics. Pharmacology |
Publisher: | Nature Publishing Group |
ISSN: | 0022-202X |
Last Modified: | 21 Oct 2022 10:41 |
URI: | https://orca.cardiff.ac.uk/id/eprint/41037 |
Citation Data
Actions (repository staff only)
Edit Item |